Obama Officially Nominates Daschle as HHS Head

Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

President-elect Barack Obama officially nominated former Senator Tom Daschle as Secretary of Health and Human Services and named him the Director of a new White House Office on Health Care Reform late last week.

Chicago (Dec. 11)-President-elect Barack Obama officially nominated former Senator Tom Daschle as Secretary of Health and Human Services and named him the Director of a new White House Office on Health Care Reform late last week. Dr. Jeanne Lambrew, of the University of Texas, will serve as Deputy Director of the White House Office of Health Reform, according to a news release from the Office of the President-elect.

"The time has come … to modernize our healthcare system for the 21st century; to reduce costs for families and businesses; and to finally provide affordable, accessible health care for every American,” said Obama in the release.

Daschle has the support of the Pharmaceutical Research and Manufacturers of America (PhRMA). He “has what it takes to do the job: smarts, toughness and a strong understanding of the healthcare challenges that face our nation in these tough economic times,” said PhRMA Chief Executive Officer Billy Tauzin in a Nov. 19 release.

The official nomination for the next commissioner of the US Food and Drug Administration is still up in the air. Several candidates’ names have been mentioned (see related blog post on PharmTech Talk).

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes